Avidity Biosciences reported positive early to mid-stage clinical data for del-zota in Duchenne muscular dystrophy, showing reversal of disease progression and functional improvements. The company brought the second-largest follow-on equity offering of the year to the market. Summit Therapeutics faced disappointing data for its PD-1xVEGF bispecific cancer drug, while Pfizer pursues a distinct VEGF bispecific strategy. Market activity reflects robust interest and competition in oncology drug pipelines and innovative modalities.